Hosted by Dave Dixon, PharmD, CLS, FNLA, this episode features an in-depth discussion with three key authors of the NLA’s new statement providing updated guidance on diagnosis, management, and treatment of FH. Together, they review the most important updates in the new guidance, including recommendations for earlier identification, the role of genetic testing and cascade screening, updated LDL-cholesterol treatment targets, and the integration of newer lipid-lowering therapies. The conversation also addresses practical considerations for managing FH across the lifespan, from pediatric care to special populations, with a focus on translating evidence-based recommendations into real-world clinical practice.
Read the NLA Expert Consensus HERE.
Podcast Listeners can claim credit for listening HERE.
